My daughter’s suddenly an AI chip expert at the dinner table, three years late but not wrong, because AEM, UMS Integration, and Frencken are all riding the same AI wave on our own exchange. AEM’s H1 profit jumped from $3.1 million to $30.8 million with guidance raised twice this year, the kind of number that should make any CPF investor sit up. But growth and income are two different tests, and today I’m showing you why a company can beat every headline and still fail the one that actually pays your bills. UMS and Frencken get their moment too, with very different scorecards.
Iggy’s Forensic Zone: Zone 3, Growth Story Without Income Story.
Key takeaways:
AEM’s H1 net profit rose nearly tenfold to $30.8 million, and FY2026 guidance was raised twice, yet it still misses my 4.7% yield hurdle by a wide margin.
Cheaper AI token costs, down more than half since May, are the mechanism DBS Group Research links to more computing demand and stronger chip equipment orders.
UMS Integration posted a 66% jump in H1 net profit, but it’s not yet on my Ledger, so I’m not calling a verdict either way.
Frencken’s H1 profit dipped 3.4%, though Q2 alone rose nearly 14%, with management guiding for a stronger second half.
A rising share price on good news doesn’t always mean the income case has improved, sometimes it means the opposite.
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
